Literature DB >> 6345362

Lithium-sodium countertransport in erythrocytes of normal and hypertensive subjects. Relationship with age and plasma renin activity.

C Brugnara, R Corrocher, L Foroni, M Steinmayr, F Bonfanti, G De Sandre.   

Abstract

Lii-Nao countertransport was measured in red blood cells of 58 normotensive subjects (27 females and 31 males), 60 patients with essential hypertension (26 females and 34 males), and in 28 with secondary hypertension (19 females and 9 males). The mean values (+/- SEM) expressed as mmol Li (1 red cells X hr)-1 were 0.18 +/- 0.02 (females) and 0.20 +/- 0.01 (males) in the control group, 0.34 +/- 0.04 (females) and 0.39 +/- 0.03 (males) in essential hypertension, 0.16 +/- 0.03 (females) and 0.19 +/- 0.02 (males) in secondary hypertension. The mean value of Lii-Nao countertransport obtained in essential hypertension was statistically different from those obtained in both normals (p less than 0.001) and patients with secondary hypertension (p less than 0.001). A negative correlation was found between age and Lii-Nao countertransport in normotensive males (r = - 0.648; p less than 0.001) but neither in normal females nor in patients with essential hypertension. A positive correlation (r = + 0.425; p less than 0.05) was found between plasma renin activity after intravenous furosemide and Lii-Nao countertransport in essential hypertension. These findings support the hypothesis of a characteristic cation transport across the red blood cell membrane of patient with essential hypertension which might be correlated with the plasma renin activity.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6345362     DOI: 10.1161/01.hyp.5.4.529

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  1 in total

Review 1.  Typology of Na+ transport abnormalities in erythrocytes from essential hypertensive patients. A first step towards the diagnosis and specific treatment of different forms of primary hypertension.

Authors:  R Garay
Journal:  Cardiovasc Drugs Ther       Date:  1990-03       Impact factor: 3.727

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.